|
1
|
Scharf JM, Miller LL, Gauvin CA, Alabiso
J, Mathews CA and Ben-Shlomo Y: Population prevalence of Tourette
syndrome: A systematic review and meta-analysis. Mov Disord.
30:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Houghton DC, Capriotti MR, Conelea CA and
Woods DW: Sensory phenomena in tourette syndrome: Their role in
symptom formation and treatment. Curr Dev Disord Rep. 1:245–251.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pauls DL, Fernandez TV, Mathews CA, State
MW and Scharf JM: The inheritance of tourette disorder: A review. J
Obsessive Compuls Relat Disord. 3:380–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paschou P, Yu D, Gerber G, Evans P,
Tsetsos F, Davis LK, Karagiannidis I, Chaponis J, Gamazon E,
Mueller-Vahl K, et al: Genetic association signal near NTN4 in
Tourette syndrome. Ann Neurol. 76:310–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prontera P, Napolioni V, Ottaviani V,
Rogaia D, Fusco C, Augello B, Serino D, Parisi V, Bernardini L,
Merla G, et al: DPP6 gene disruption in a family with Gilles de la
Tourette syndrome. Neurogenetics. 15:237–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leckman JF: Tourette's syndrome. Lancet.
360:1577–1586. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singer HS, Hahn IH and Moran TH: Abnormal
dopamine uptake sites in postmortem striatum from patients with
Tourette's syndrome. Ann Neurol. 30:558–562. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wolf SS, Jones DW, Knable MB, Gorey JG,
Lee KS, Hyde TM, Coppola R and Weinberger DR: Tourette syndrome:
Prediction of phenotypic variation in monozygotic twins by caudate
nucleus D2 receptor binding. Science. 273:1225–1227. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Minzer K, Lee O, Hong JJ and Singer HS:
Increased prefrontal D2 protein in Tourette syndrome: A postmortem
analysis of frontal cortex and striatum. J Neurol Sci. 219:55–61.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haugbol S, Pinborg LH, Regeur L, Hansen
ES, Bolwig TG, Nielsen FA, Svarer C, Skovgaard LT and Knudsen GM:
Cerebral 5-HT2A receptor binding is increased in patients with
Tourette's syndrome. Int J Neuropsychopharmacol. 10:245–252. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martino D and Pringsheim TM: Tourette
syndrome and other chronic tic disorders: An update on clinical
management. Expert Rev Neurother. 18:125–137. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leckman JF, Bloch MH, Smith ME, Larabi D
and Hampson M: Neurobiological substrates of Tourette's disorder. J
Child Adolesc Psychopharmacol. 20:237–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
George MS, Robertson MM, Costa DC, Trimble
MR, Pilowsky L and Verhoeff NP: Dopamine receptor availability in
Tourette's syndrome. Psychiatry Res. 55:193–203. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singer HS, Szymanski S, Giuliano J, Yokoi
F, Dogan AS, Brasic JR, Zhou Y, Grace AA and Wong DF: Elevated
intrasynaptic dopamine release in Tourette's syndrome measured by
PET. Am J Psychiatry. 159:1329–1336. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong DF, Brasic JR, Singer HS, Schretlen
DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, et
al: Mechanisms of dopaminergic and serotonergic neurotransmission
in Tourette syndrome: Clues from an in vivo neurochemistry study
with PET. Neuropsychopharmacology. 33:1239–1251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kakhi S and Soomro GM: Obsessive
compulsive disorder in children and adolescents: Duration of
maintenance drug treatment. BMJ Clin Evid. 2015:2015.
|
|
17
|
McDougle CJ, Epperson CN, Pelton GH,
Wasylink S and Price LH: A double-blind, placebo-controlled study
of risperidone addition in serotonin reuptake inhibitor-refractory
obsessive-compulsive disorder. Arch Gen Psychiatry. 57:794–801.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cadet JL: The iminodipropionitrile
(IDPN)-induced dyskinetic syndrome: behavioral and biochemical
pharmacology. Neurosci Biobehav Rev. 13:39–45. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ogawa N, Mizukawa K, Haba K and Sato H:
Neurotransmitter and receptor alterations in the rat persistent
dyskinesia model induced by iminodipropionitrile. Eur Neurol. 30
(Suppl 1):S31–S40. 1990. View Article : Google Scholar
|
|
20
|
Zhang F and Li A: Dual ameliorative
effects of Ningdong granule on dopamine in rat models of Tourette's
syndrome. Sci Rep. 5:77312015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao L, Li AY, Lv H, Liu FY and Qi FH:
Traditional Chinese medicine Ningdong granule: The beneficial
effects in Tourette's disorder. J Int Med Res. 38:169–175. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li JJ, Li ZW, Wang SZ, Qi FH, Zhao L, Lv H
and Li AY: Ningdong granule: A complementary and alternative
therapy in the treatment of attention deficit/hyperactivity
disorder. Psychopharmacology (Berl). 216:501–509. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Egolf A and Coffey BJ: Current
pharmacotherapeutic approaches for the treatment of Tourette
syndrome. Drugs Today (Barc). 50:159–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ernst M, Zametkin AJ, Jons PH, Matochik
JA, Pascualvaca D and Cohen RM: High presynaptic dopaminergic
activity in children with Tourette's disorder. J Am Acad Child
Adolesc Psychiatry. 38:86–94. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gilbert DL, Christian BT, Gelfand MJ, Shi
B, Mantil J and Sallee FR: Altered mesolimbocortical and thalamic
dopamine in Tourette syndrome. Neurology. 67:1695–1697. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hwang WJ, Yao WJ, Fu YK and Yang AS:
[99mTc]TRODAT-1/[123I]IBZM SPECT studies of the dopaminergic system
in Tourette syndrome. Psychiatry Res. 162:159–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grace AA: Phasic versus tonic dopamine
release and the modulation of dopamine system responsivity: A
hypothesis for the etiology of schizophrenia. Neuroscience.
41:1–24. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dahlstroem A and Fuxe K: Evidence for the
existence of monoamine-containing neurons in the central nervous
System. I. demonstration of monoamines in the cell bodies of brain
stem neurons. Acta Physiol Scand. 232 (Suppl):S231–S255. 1964.
|
|
29
|
Butcher LL and Woolf NJ: Cholinergic and
serotonergic systems in the brain and spinal cord: Anatomic
organization, role in intercellular communication processes, and
interactive mechanisms. Prog Brain Res. 55:1–40. 1982.PubMed/NCBI
|
|
30
|
Lodge DJ and Grace AA: The hippocampus
modulates dopamine neuron responsivity by regulating the intensity
of phasic neuron activation. Neuropsychopharmacology. 31:1356–1361.
2006. View Article : Google Scholar : PubMed/NCBI
|
